Press Room

With CMTA support of $302,071, an international team of researchers from the Inherited Neuropathies Consortium, led by Micheal Shy, MD, at the University of Iowa in Iowa City, IA, is studying the natural history of ...

Help for Today and Hope for Tomorrow: Empowering the CMT Community at the 2024 CMTA Patient & Research Summit in Denver The 2024 CMTA Patient & Research Summit in Colorado was a remarkable gathering of more ...

The Charcot-Marie-Tooth Association (CMTA) continues its mission to accelerate research that impacts the lives of those living with Charcot-Marie-Tooth disease (CMT) and is excited to share progress in a CRISPR research project focused on developing ...

CMT2S: A Potential New Treatment on the Horizon Charcot-Marie-Tooth Disease Type 2S (CMT2S) is a severe axonal type of CMT caused by certain autosomal recessive mutations of the IGHMBP2 gene. CMTA-STAR Alliance Partner Vanda Pharmaceuticals ...

The Charcot-Marie-Tooth Association (CMTA) continues its mission to accelerate research that impacts the lives of those living with Charcot-Marie-Tooth disease (CMT). Building on previous successes, CMTA announced earlier this year a strategic $450,000 investment in ...